Patents by Inventor Yasushi Yamazoe
Yasushi Yamazoe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160244848Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: April 29, 2016Publication date: August 25, 2016Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Yasushi YAMAZOE, Kiyoshi NAGATA
-
Publication number: 20160025706Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: October 6, 2015Publication date: January 28, 2016Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Yasushi YAMAZOE, Kiyoshi NAGATA
-
Publication number: 20150185203Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: March 12, 2015Publication date: July 2, 2015Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Yasushi YAMAZOE, Kiyoshi Nagata
-
Publication number: 20140363810Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: August 25, 2014Publication date: December 11, 2014Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Yasushi YAMAZOE, Kiyoshi NAGATA
-
Publication number: 20140127706Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene an;d at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: December 20, 2013Publication date: May 8, 2014Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Yasushi YAMAZOE, Kiyoshi Nagata
-
Publication number: 20130164735Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: January 30, 2013Publication date: June 27, 2013Inventors: Yasushi Yamazoe, Kiyoshi Nagata
-
Publication number: 20120264112Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: April 26, 2012Publication date: October 18, 2012Applicants: DAIICHI PURE CHEMICALS CO., LTD.Inventors: Yasushi YAMAZOE, Kiyoshi NAGATA
-
Publication number: 20110229875Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that anon-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: April 4, 2011Publication date: September 22, 2011Applicants: Yasushi YAMAZOE, DAIICHI PURE CHEMICALS CO., LTD.Inventors: Yasushi Yamazoe, Kiyoshi Nagata
-
Patent number: 7910362Abstract: A reporter vector which can evaluate the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 and a method for evaluation of the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 by using the reporter vector. A reporter system which can evaluate the ability of a drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 is completed by constructing a reporter vector having a reporter gene linked to the 3? end of a region between CYP1A1 and CYP1A2 or a reporter vector having different reporter genes linked to the both ends of the region, respectively, so as to sandwich the region, and a reporter vector having a deletion mutation in the region, and confirming that the expression of a reporter molecule is increased by the drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 in the reporter system using the reporter vector.Type: GrantFiled: July 12, 2006Date of Patent: March 22, 2011Assignees: Eisai R&D Management Co., Ltd., Tohoku UniversityInventors: Rika Ueda, Kazutomi Kusano, Yasushi Yamazoe, Kiyoshi Nagata
-
Publication number: 20110029296Abstract: A ring structure of a predicted target compound which is in a two-dimensional structural formula is arranged so as to be in an identical position as a ring structure of a template produced by superimposing two-dimensional structural formulae of compounds capable of forming a complex with a predetermined enzyme. Among predicted target compounds overlapping with a metabolic target site of the template, predicted target compounds other than those determined as being unable to access a metabolic active center site of the enzyme, or those having the same charge as that of the metabolic active center site, are determined to be metabolizable compounds. Based on the level of contribution of each atom included in the template during a metabolic reaction of the enzyme, a structural formula of a compound obtained after the metabolic reaction of the metabolizable compound whose metabolic target site has been determined is determined.Type: ApplicationFiled: June 30, 2010Publication date: February 3, 2011Applicants: FUJITSU LIMITED, TOHOKU UNIVERSITYInventors: Jose Martin Ciloy, Masato Kitajima, Yasushi Yamazoe
-
Publication number: 20090317800Abstract: A reporter vector which can evaluate the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 and a method for evaluation of the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 by using the reporter vector. A reporter system which can evaluate the ability of a drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 is completed by constructing a reporter vector having a reporter gene linked to the 3? end of a region between CYP1A1 and CYP1A2 or a reporter vector having different reporter genes linked to the both ends of the region, respectively, so as to sandwich the region, and a reporter vector having a deletion mutation in the region, and confirming that the expression of a reporter molecule is increased by the drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 in the reporter system using the reporter vector.Type: ApplicationFiled: July 12, 2006Publication date: December 24, 2009Applicants: Eisai R&D Management Co., Ltd., Tohoku UniversityInventors: Rika Ueda, Kazutomi Kusano, Yasushi Yamazoe, Kiyoshi Nagata
-
Publication number: 20090029351Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: July 28, 2008Publication date: January 29, 2009Applicants: Yasushi YAMAZOE, DAIICHI PURE CHEMICALS CO., LTD.Inventors: Yasushi YAMAZOE, Kiyoshi Nagata
-
Publication number: 20070016392Abstract: A drug-metabolizing enzyme prediction apparatus acquires compound structure information, identifies binding site information and molecular species information based on a binding-site identifying condition, specifies a pinching point that is an atom binding at least between a reactive site and a binding site, acquires pinching point information on the specified pinching point and reactive site information on the reactive site bound to the pinching point, and identifies the acquired reactive site information based on a reactive-site identifying condition and the acquired pinching point information based on a pinching-point identifying condition.Type: ApplicationFiled: September 21, 2006Publication date: January 18, 2007Applicants: FUJITSU LIMITED, Yasushi YAMAZOEInventors: Masato Kitajima, Jose Ciloy, Yasushi Yamazoe
-
Publication number: 20060194248Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: May 1, 2006Publication date: August 31, 2006Applicants: Yasushi Yamazoe, DAIICHI PURE CHEMICALS CO., LTD.Inventors: Yasushi Yamazoe, Kiyoshi Nagata
-
Publication number: 20050142064Abstract: A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.Type: ApplicationFiled: April 15, 2003Publication date: June 30, 2005Inventors: Yasushi Yamazoe, Kiyoshi Nagata